262 related articles for article (PubMed ID: 12207635)
1. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
Coller JK; Krebsfaenger N; Klein K; Endrizzi K; Wolbold R; Lang T; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
Br J Clin Pharmacol; 2002 Aug; 54(2):157-67. PubMed ID: 12207635
[TBL] [Abstract][Full Text] [Related]
2. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of tamoxifen therapy.
Brauch H; Mürdter TE; Eichelbaum M; Schwab M
Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
[TBL] [Abstract][Full Text] [Related]
6. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
7. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
Chang Y; Fang WB; Lin SN; Moody DE
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):55-62. PubMed ID: 20825389
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
12. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
Watanabe M; Watanabe N; Maruyama S; Kawashiro T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
[TBL] [Abstract][Full Text] [Related]
13. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
14. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.
Rehmel JL; Eckstein JA; Farid NA; Heim JB; Kasper SC; Kurihara A; Wrighton SA; Ring BJ
Drug Metab Dispos; 2006 Apr; 34(4):600-7. PubMed ID: 16415119
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.
Mazzarino M; Biava M; de la Torre X; Fiacco I; Botrè F
Anal Bioanal Chem; 2013 Jun; 405(16):5467-87. PubMed ID: 23604525
[TBL] [Abstract][Full Text] [Related]
16. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
Jacobson PA; Green K; Birnbaum A; Remmel RP
Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
[TBL] [Abstract][Full Text] [Related]
18. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
Mürdter TE; Schroth W; Bacchus-Gerybadze L; Winter S; Heinkele G; Simon W; Fasching PA; Fehm T; ; Eichelbaum M; Schwab M; Brauch H
Clin Pharmacol Ther; 2011 May; 89(5):708-17. PubMed ID: 21451508
[TBL] [Abstract][Full Text] [Related]
19. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
20. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
